Literature DB >> 26648620

Perampanel.

.   

Abstract

Entities:  

Year:  2014        PMID： 26648620      PMCID： PMC4653993          DOI： 10.18773/austprescr.2015.025

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  5 in total

Review 1.  The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis.

Authors:  Nasreen Khan; Dhvani Shah; Vanita Tongbram; Lara Verdian; Neil Hawkins
Journal:  Curr Med Res Opin       Date:  2013-06-19       Impact factor: 2.580

2.  Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Authors:  G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

3.  Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

Authors:  Jacqueline A French; Gregory L Krauss; Victor Biton; David Squillacote; Haichen Yang; Antonio Laurenza; Dinesh Kumar; Michael A Rogawski
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

4.  Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

Authors:  Jacqueline A French; Gregory L Krauss; Bernhard J Steinhoff; David Squillacote; Haichen Yang; Dinesh Kumar; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

5.  Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Authors:  Bernhard J Steinhoff; Elinor Ben-Menachem; Philippe Ryvlin; Simon Shorvon; Lynn Kramer; Andrew Satlin; David Squillacote; Haichen Yang; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2013-05-10       Impact factor: 5.864
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.